RoActemra

This page shows the latest RoActemra news and features for those working in and with pharma, biotech and healthcare.

Roche's Actemra/RoActemra receives new European approval

Roche's Actemra/RoActemra receives new European approval. EU regulators also pass the Swiss pharma firm’s Gazyvaro. ... As the first effective non-steroid therapy for GCA, Actemra/RoActemra has the potential to fundamentally change how this condition

Latest news

Ocrevus off to a flying start as Roche raises 2017 forecasts

Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks
Sanofi/Regeneron bag first approval for Actemra rival sarilumab

Sarilumab is a fully human monoclonal antibody that binds specifically to both soluble and membrane-bound IL-6 receptors, and is the first direct competitor to Roche's Actemra/RoActemra (tocilizumab)
Manufacturing issues scupper Sanofi's sarilumab launch plans

Any delay to the programme is however a blow to Sanofi and Regeneron, which are playing catch-up against the only marketed IL-6 inhibitor - Roche's Actemra/RoActemra (tocilizumab) - while
Roche snags pair of FDA breakthrough designations

Meanwhile, Roche's interleukin-6 inhibitor RoActemra/Actemra (tocilizumab) picked up a BTD for giant cell arteritis, a chronic and potentially life-threatening autoimmune condition in which serious inflammation is seen
Cancer drugs help Roche beat expectations in first quarter

RoActemra (tocilizumab) added 14% to reach CHF386m.

More from news
Approximately 5 fully matching, plus 26 partially matching documents found.

Latest Intelligence

Opening up innovation

If approved it will compete with the likes of Roche's RoActemra (tocilizumab). “

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

Infographic: RA Perceptions

Partnership. An infographic highlights the key findings from the study. Biologic agents with novel mechanisms of action (such as Roche’ s RoActemra) are expected to outperform the overall EU biologics market
The Biosimilar Challenge

Herceptin, Avastin, Rituximab and Erbitux) and autoimmune disease (e.g. Humira, Enbrel, Remicade, MabThera and RoActemra to name a few).
Brand leaders in RA will lose market share, predict rheumatologists

market leaders Enbrel (etanercept) and Humira (adalimumab) will continue to lose market share to newer biologics such as RoActemra (tocilizumab), Orencia (abatacept) and Simponi (golimumab) and may experience strong competition from

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Medical Writer - (London, Brighton or Copenhagen): Competitive

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Account Manager – Med Comms – London: Salary TBC

Scientific Director: Great salary and bebefits

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Senior Medical Writer: Great salary and benefits

Editorial Director – Medical Education – Oxford: Negotiable

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

Senior Account Manager – Med Comms – Kent: Salary TBC

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Medical Writer: Great salary and bebefits

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Programme Executive: Salary TBC

Account Director - Global Healthcare Advertising (Digital) - Lon...: £55000 - £65000

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Senior Account Manager / Account Director: Great salary and bebefits

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Account Manager or AD - Medical Communications: Salary TBC

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Subscribe to our email news alerts

PMHub

Add my company

Four Health Communications

Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...

Latest intelligence

No incentive for a cure: The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...